title: Monocyte development inhibitor PRM-151 decreases corneal myofibroblast generation in rabbits.
abstract: This study investigated whether PRM-151 (Promedior, Inc., Malvern, PA), a recombinant form of human pentraxin-2 (PTX-2, also referred to as serum amyloid P, hSAP), that inhibits differentiation of circulating monocytes into fibrocytes and profibrotic macrophages, could modulate generation of myofibroblasts after opacity-producing corneal injury in rabbits, and, therefore, have potential to reduce or prevent haze after PRK. Nine diopter PRK for myopia was performed with the VISX S4 IR laser. Four groups of 6 animals were treated in masked fashion: Group 1: 30 μl of topical PRM-151 (20 mg/ml) 6 times a day for 5 days; Group 2: 30 μl topical vehicle 6 times a day for 5 days; Group 3: 200 μl sub-conjunctival PRM-151 (total injection of 4 mg) immediately after surgery and every other day until day 8; Group 4: 200 μl sub-conjunctival injections of vehicle according to the same schedule as group 3. At one month after PRK, the animals were euthanized and immunohistochemistry was performed for the myofibroblast marker α-smooth muscle actin (SMA). The density of SMA+ cells/400× field in the central stroma was determined in each cornea. Myofibroblast density at one month after surgery was significantly lower (p = 0.006) after sub-conjunctival PRM-151 treatment (5.8 ± 2.8 cells/400× stromal field) compared to sub-conjunctival vehicle treatment (15.3 ± 2.9 cells/400× stromal field). There was no significant (p = 0.27) decrease in stromal myofibroblasts triggered by topical PRM-151 treatment (11.8 ± 6.6 cells/400× stromal field) compared to the topical vehicle treatment (14.2.8 ± 6.2 cells/400× stromal field). PRM-151 inhibits myofibroblast generation when administered by sub-conjunctival injection, but not when administered topically, after opacity-producing corneal injury. This study provides additional confirmation that bone marrow-derived cells contribute to corneal myofibroblast generation.
authors.forename: M R
authors.initials: MR
authors.lastname: Santhiago
authors.forename: V
authors.initials: V
authors.lastname: Singh
authors.forename: F L
authors.initials: FL
authors.lastname: Barbosa
authors.forename: V
authors.initials: V
authors.lastname: Agrawal
authors.forename: S E
authors.initials: SE
authors.lastname: Wilson
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D002452:Cell Count; D002454:Cell Differentiation / Q000187:drug effects; D065306:Corneal Injuries; D003318:Corneal Opacity / Q000378:metabolism / Q000517:prevention & control*; D003319:Corneal Stroma / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D019084:Fluorescent Antibody Technique, Indirect; D018398:Homeodomain Proteins / Q000008:administration & dosage*; D056965:Injections, Intraocular; D054018:Lasers, Excimer; D009000:Monocytes / Q000187:drug effects*; D058628:Myofibroblasts / Q000378:metabolism*; D009216:Myopia / Q000601:surgery; D018903:Photorefractive Keratectomy; D011817:Rabbits; D011994:Recombinant Proteins / Q000008:administration & dosage; D000683:Serum Amyloid P-Component / Q000008:administration & dosage*
chemical_list: D000199:Actins; D018398:Homeodomain Proteins; C552898:PRM-151; D011994:Recombinant Proteins; D000683:Serum Amyloid P-Component